ABSTRACT
The monochromatic excimer light therapy (308-nm excimer laser and lamp) is used to treat focal dermatoses with inflammation or hypopigmentation. In Australia, despite excimer light therapy being a proven effective treatment for many cutaneous conditions, barriers such as access and affordability provide considerable limitations to patients. This study aims to retrospectively evaluate the different applications of excimer light therapy in treating dermatologic conditions within the Australian setting and provide practical information for its use.
Subject(s)
Dermatology/methods , Hypopigmentation/radiotherapy , Low-Level Light Therapy , Australia , Humans , Retrospective Studies , Treatment OutcomeSubject(s)
Ambulatory Care Facilities , Skin Diseases/epidemiology , Skin Diseases/physiopathology , Adolescent , Adult , Aged , Female , Fiji/epidemiology , Humans , Male , Middle Aged , Retrospective Studies , Young AdultABSTRACT
BACKGROUND/OBJECTIVES: Vulval lichen sclerosus (VLS) is a chronic inflammatory skin condition predominantly affecting the anogenital region in women and children. To date, there is lack of agreement amongst experts on a severity scale to aid assessment, research and treatment stratification on VLS. Furthermore, literature on best practice for long-term management of VLS is lacking. The aim of this consensus is to provide broad guidelines on the short and long-term management of VLS. METHODS: An initial focus group of Australasian experts in vulval dermatology developed a draft consensus statement for the management of VLS. Based on the results of the draft statement, a consensus panel of 22 Australasian experts, comprised of the initial and additional members, participated in an anonymous four-stage eDelphi process. Round 1 involved generation and voting on statements from the draft consensus statement developed by the focus group. In Rounds 2, 3 & 4, panel members were presented formal feedback from previous rounds and asked to indicate their level of agreement. Consensus was reached if there was ≥70% agreement on the importance of an item in the 4 (agree) to 5 (strongly agree) range. RESULTS: The expert panel, with a total of 504 collective years of experience in the field of VLS, reached consensus on a core set of 51 management statements related to diagnosis, severity, initial and long-term management, follow-up, and complications of VLS. CONCLUSIONS: This study has identified a set of management statements for VLS that may be useful in clinical practice in the Australasian population.
Subject(s)
Consensus , Lichen Sclerosus et Atrophicus/therapy , Practice Guidelines as Topic/standards , Practice Patterns, Physicians'/standards , Vulvar Lichen Sclerosus/therapy , Dermatologists/standards , Female , Humans , Lichen Sclerosus et Atrophicus/prevention & control , Vulvar Lichen Sclerosus/prevention & controlSubject(s)
Botulinum Toxins/adverse effects , Mycobacteriaceae/isolation & purification , Mycobacterium Infections/chemically induced , Neuromuscular Agents/adverse effects , Skin Diseases, Bacterial/chemically induced , Adult , Female , Humans , Mycobacterium Infections/microbiology , Skin Diseases, Bacterial/microbiologyABSTRACT
Eosinophilic cellulitis is a rare inflammatory skin disease of unknown aetiology, first described by George Wells in 1971 as a recurrent granulomatous dermatitis with eosinophilia. It is typically characterised by recurrent pruritic erythematous plaques, vesicles or bullae usually involving the extremities and trunk. Many cases of eosinophilic cellulitis are difficult to treat and traditionally require long course of oral steroids, resulting in steroid side effects. This case adds to the literature in that we report the use of methotrexate to treat eosinophilic cellulitis, as a safe and efficacious therapeutic alternative.
